TIDMPOLX
RNS Number : 6861E
Polarean Imaging PLC
09 July 2021
Polarean Imaging Plc
("Polarean" or the "Company")
Grant of Options and Director Compensation Reduction
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with an investigational proprietary drug-device
combination product for the magnetic resonance imaging (MRI)
market, announces that upon the recommendation of the Company's
Remuneration Committee it has granted options over an aggregate
5,250,000 shares of GBP 0.00037 each in the capital of the Company
to certain Directors and employees of the Company pursuant to the
terms of the Company's Stock Option Plan (the "Share Options"). In
addition, the Company announces that the Chairman and Non-Executive
Directors have agreed to reduce their annual cash compensation.
4,450,000 Share Options have been granted to the ten PDMR's
listed in the table below and 800,000 Share Options have been
granted to eight non-PDMR employees. The Share Options will be
exercisable at a price of 93p and will vest 25% on 7 July 2022 with
the remaining Share Options vesting in equal portions on the last
day of each calendar month over the period of 36 months starting on
31 August 2022.
Name Share Options Granted Total no. of options
over ordinary shares
now held
Richard Hullihen 1,000,000 3,135,440
---------------------- ----------------------
Jonathan Allis 500,000 1,034,400
---------------------- ----------------------
Cyrille Petit 500,000 500,000
---------------------- ----------------------
Charles Osborne 500,000 1,700,000
---------------------- ----------------------
Kenneth West 350,000 2,263,218
---------------------- ----------------------
Bastiaan Driehuys 350,000 1,686,000
---------------------- ----------------------
Juergen Laucht 350,000 884,400
---------------------- ----------------------
Kiarash Emami 300,000 3,185,548
---------------------- ----------------------
Neil Wadehra 300,000 1,568,988
---------------------- ----------------------
Alexander Dusek 300,000 1,500,000
---------------------- ----------------------
Notifications have been made in accordance with the requirements
of the EU Market Abuse Regulation in respect of the PDMRs and
further details can be found by following this link:
https://www.polarean-ir.com/content/investors/shareholder-information
Dr. Jonthan Allis has agreed to reduce his annual cash
compensation f rom $100,000 to $70,000. Dr. Bastiaan Driehuys, Mr.
Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed
reduce their base annual cash compensation from $45,000 to $31,500.
Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr.
Juergen Laucht will continue to receive an additional $5,000 per
year for each Board Committee on which they serve.
Following the grant of Share Options referred above, there are
26,438,451 outstanding options and warrants over Polarean's
Ordinary Shares, representing 12.6% of the Company's total voting
rights.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams / Fred Walsh (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44
(0)7879 741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, investigational
drug-device combination companies operating in the high-resolution
medical imaging research space.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation. (129) Xe gas is currently
being studied for visualisation of gas exchange regionally in the
smallest airways of the lungs, across the alveolar tissue barrier,
and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application
("NDA") to the FDA for hyperpolarised (129) Xe used to evaluate
pulmonary function and to visualise the lung using MRI. In December
2020, the Group received confirmation of acceptance of its NDA by
the FDA, with a target PDUFA action date of 5 October 2021.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel investigational
diagnostic approach, offering a non-invasive and radiation-free
functional imaging platform. The annual burden of pulmonary disease
in the US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCRPMPTMTTMBMB
(END) Dow Jones Newswires
July 09, 2021 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024
